A biotech boom for the ASX? This fundie thinks so

Alex GluyasMarkets reporter

Jun 6, 2024 – 2.04pm

Subscribe to gift this article

Gift 5 articles to anyone you choose each month when you subscribe.

Already a subscriber?

Rory Hunter is portfolio manager of SG Hiscock’s Medical Technology Fund.
The Melbourne-based investment firm oversees $4.2 billion in assets.

Some analysts have suggested CSL could get to $500, do you think that’s plausible?

Alex Gluyas is a markets reporter based in our Melbourne newsroom. Connect with Alex on Twitter. Email Alex at alex.gluyas@afr.com

Subscribe to gift this article

Gift 5 articles to anyone you choose each month when you subscribe.

Already a subscriber?

Introducing your Newsfeed

Follow the topics, people and companies that matter to you.

Fetching latest articles